Par Pharmaceutical Put Older Patients at Risk Marketing Megace ES
Par Pharmaceutical Put Older Patients at Risk Marketing Megace ES
The problem is that the U.S. Food and Drug Administration had approved Megace ES only to treat weight loss associated with AIDS. In fact, the FDA had twice instructed the company to do additional research and clinical trials if it wanted to market the drug for other uses. Par, however, continued targeting doctors and nursing homes caring for non-AIDs geriatric patients. The company rewarded top-performing sales reps with bonuses such as Rolex watches and vacations to Mexico. In March, facing a raft of criminal and civil lawsuits over its "off-label" marketing of Megace ES, the company pleaded guilty in federal court to misbranding its product and agreed to pay $45 million in penalties. Par Pharmaceutical had earned $11 million through its "end run" around the FDA, U.S. Attorney Paul Fishman said. Although no allegations exist that anyone was harmed, the Justice Department says Par was aware of the potential side effects associated with the drug, including "an increased risk of , toxic reactions in elderly patients with impaired renal function, and mortality."
Savings, resources and news for your well-being Visit the every day for great deals and for tips on keeping healthy and sharp Cancel You are leaving AARP.org and going to the website of our trusted provider. The provider’s terms, conditions and policies apply. Please return to AARP.org to learn more about other benefits. Your email address is now confirmed. You'll start receiving the latest news, benefits, events, and programs related to AARP's mission to empower people to choose how they live as they age. You can also by updating your account at anytime. You will be asked to register or log in. Cancel Offer Details Disclosures
Par Pharmaceutical Nabbed Put Older Patients At Risk With Weight-Gain Drug Megace ES
More on Drug Safety
Drug company put elderly at risk with off-label marketing of Megace ES. l For nearly eight years, New Jersey-based Par Pharmaceutical made millions of dollars by aggressively pushing Megace ES as a weight-gain drug for patients in nursing homes and other long-term care facilities.The problem is that the U.S. Food and Drug Administration had approved Megace ES only to treat weight loss associated with AIDS. In fact, the FDA had twice instructed the company to do additional research and clinical trials if it wanted to market the drug for other uses. Par, however, continued targeting doctors and nursing homes caring for non-AIDs geriatric patients. The company rewarded top-performing sales reps with bonuses such as Rolex watches and vacations to Mexico. In March, facing a raft of criminal and civil lawsuits over its "off-label" marketing of Megace ES, the company pleaded guilty in federal court to misbranding its product and agreed to pay $45 million in penalties. Par Pharmaceutical had earned $11 million through its "end run" around the FDA, U.S. Attorney Paul Fishman said. Although no allegations exist that anyone was harmed, the Justice Department says Par was aware of the potential side effects associated with the drug, including "an increased risk of , toxic reactions in elderly patients with impaired renal function, and mortality."
Also of Interest br
Savings, resources and news for your well-being Visit the every day for great deals and for tips on keeping healthy and sharp Cancel You are leaving AARP.org and going to the website of our trusted provider. The provider’s terms, conditions and policies apply. Please return to AARP.org to learn more about other benefits. Your email address is now confirmed. You'll start receiving the latest news, benefits, events, and programs related to AARP's mission to empower people to choose how they live as they age. You can also by updating your account at anytime. You will be asked to register or log in. Cancel Offer Details Disclosures